SEYMOUR S. CUTLER, M.D.; BENJAMIN BURBANK, M.D., F.A.C.P.; BIAGIO BATTAGLIA, M.D., F.A.C.P.
This content is PDF only. Please click on the PDF icon to access.
Since 1944, the mainstay in drug therapy of tuberculosis has been streptomycin. This drug, especially in combination with para-amino-salicylic acid (PAS) and when used in dosage schedules designed to delay the emergence of resistant strains of Mycobacterium tuberculosis, has revolutionized the course and the prognosis of pulmonary and extrapulmonary tuberculosis. Nevertheless, the obvious drawbacks of streptomycin, such as its production of neurotoxic symptoms, allergic reactions and bacterial resistance, have encouraged the search for other mycobactericidal agents. A recent advance has been the development of hydrazine derivatives of isonicotinic acid.
The most promising of these compounds is isonicotinic acid hydrazide, Isoniazid
CUTLER SS, BURBANK B, BATTAGLIA B. CLINICAL EVALUATION OF ISONIAZID*. Ann Intern Med. 1953;39:444–462. doi: https://doi.org/10.7326/0003-4819-39-3-444
Download citation file:
Published: Ann Intern Med. 1953;39(3):444-462.
Education and Training.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use